JP5765813B2 - 治療用ペプチドのポリマーコンジュゲート - Google Patents

治療用ペプチドのポリマーコンジュゲート Download PDF

Info

Publication number
JP5765813B2
JP5765813B2 JP2011527822A JP2011527822A JP5765813B2 JP 5765813 B2 JP5765813 B2 JP 5765813B2 JP 2011527822 A JP2011527822 A JP 2011527822A JP 2011527822 A JP2011527822 A JP 2011527822A JP 5765813 B2 JP5765813 B2 JP 5765813B2
Authority
JP
Japan
Prior art keywords
peptide
mpeg
therapeutic
conjugate
therapeutic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011527822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502990A (ja
JP2012502990A5 (enExample
Inventor
メアリー ジェイ． ボサード，
メアリー ジェイ． ボサード，
スティーブン オー． ロクツニアック，
スティーブン オー． ロクツニアック，
ハロルド ザッペ，
ハロルド ザッペ，
ユージュン ワン，
ユージュン ワン，
ピン チャン，
ピン チャン，
ダーウェイ シェン，
ダーウェイ シェン，
シー． シモーヌ ジュード−フィッシュバーン，
シー． シモーヌ ジュード−フィッシュバーン，
エリザベス ミナミタニ，
エリザベス ミナミタニ，
シャオフェン リュー，
シャオフェン リュー，
ハイム モスコウィッツ，
ハイム モスコウィッツ，
デニス フライ，
デニス フライ，
シェリー アリ，
シェリー アリ，
クリスティン テイラー ブルー，
クリスティン テイラー ブルー，
Original Assignee
ウェルズ ファーゴ バンク ナショナル アソシエイション
ウェルズ ファーゴ バンク ナショナル アソシエイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェルズ ファーゴ バンク ナショナル アソシエイション, ウェルズ ファーゴ バンク ナショナル アソシエイション filed Critical ウェルズ ファーゴ バンク ナショナル アソシエイション
Publication of JP2012502990A publication Critical patent/JP2012502990A/ja
Publication of JP2012502990A5 publication Critical patent/JP2012502990A5/ja
Application granted granted Critical
Publication of JP5765813B2 publication Critical patent/JP5765813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011527822A 2008-09-19 2009-09-17 治療用ペプチドのポリマーコンジュゲート Expired - Fee Related JP5765813B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19267208P 2008-09-19 2008-09-19
US61/192,672 2008-09-19
US20808909P 2009-02-18 2009-02-18
US61/208,089 2009-02-18
US15396609P 2009-02-19 2009-02-19
US61/153,966 2009-02-19
PCT/US2009/005192 WO2010033207A1 (en) 2008-09-19 2009-09-17 Polymer conjugates of therapeutic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015092575A Division JP2015134832A (ja) 2008-09-19 2015-04-30 治療用ペプチドのポリマーコンジュゲート

Publications (3)

Publication Number Publication Date
JP2012502990A JP2012502990A (ja) 2012-02-02
JP2012502990A5 JP2012502990A5 (enExample) 2012-08-23
JP5765813B2 true JP5765813B2 (ja) 2015-08-19

Family

ID=41226622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011527822A Expired - Fee Related JP5765813B2 (ja) 2008-09-19 2009-09-17 治療用ペプチドのポリマーコンジュゲート
JP2015092575A Pending JP2015134832A (ja) 2008-09-19 2015-04-30 治療用ペプチドのポリマーコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015092575A Pending JP2015134832A (ja) 2008-09-19 2015-04-30 治療用ペプチドのポリマーコンジュゲート

Country Status (7)

Country Link
US (5) US8680263B2 (enExample)
EP (3) EP2350118B1 (enExample)
JP (2) JP5765813B2 (enExample)
AU (1) AU2009292643B2 (enExample)
CA (1) CA2737040C (enExample)
MX (1) MX2011003117A (enExample)
WO (2) WO2010033207A1 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2007262635B2 (en) 2006-06-23 2014-09-11 Adc Therapeutics Sa Polynucleotides and polypeptide sequences involved in cancer
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
US20110171165A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
EP2334333A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of v681-like peptides
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
EP2340047A1 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033220A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033217A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
US20110171161A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011035065A1 (en) * 2009-09-17 2011-03-24 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN103119055A (zh) * 2010-05-17 2013-05-22 塞比克斯公司 聚乙二醇化c肽
PL2603600T3 (pl) 2010-08-13 2019-06-28 Aileron Therapeutics, Inc. Makrocykle peptidomometyczne
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
JP2014506116A (ja) 2010-11-12 2014-03-13 ウェルズ ファーゴ バンク ナショナル アソシエイション Ｉｌ−２部分とポリマーとのコンジュゲート
KR101908152B1 (ko) 2011-01-04 2018-10-15 가트 테크놀로지스 비.브이. 친전자적으로 활성화된 폴리옥사졸린으로부터 유도된 교차-결합된 중합체 및 임플란트
SMT201900505T1 (it) 2011-03-31 2019-11-13 Adc Therapeutics Sa Anticorpi contro l'antigene 1 associato ai reni e loro frammenti leganti l'antigene
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
SG10201606243YA (en) * 2011-06-02 2016-09-29 Prolor Biotech Inc Long-acting glp-1/glucagon receptor agonists
MX391293B (es) 2011-06-10 2025-03-21 Hanmi Science Co Ltd DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS.
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
KR101997939B1 (ko) 2011-08-12 2019-07-08 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
CA2852468A1 (en) * 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8916680B2 (en) 2011-11-23 2014-12-23 Quest Diagnostics Investments, Inc. Kisspeptin-54 detection by tandem mass spectrometry
BR112014016338B1 (pt) 2012-01-02 2021-01-26 Universiteit Gent polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos
PT2802351T (pt) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
ES2425448B8 (es) * 2012-03-12 2015-03-17 Universidade De Santiago De Compostela Uso de la obestatina para la regeneración muscular
CN104271638B (zh) 2012-03-16 2016-11-02 本德尔分析控股公司 源于亲核活性聚噁唑啉的交联聚合物和医用品
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
UA109760C2 (uk) * 2012-05-21 2015-09-25 Біологічно активні пептидні комплекси
EA201492269A1 (ru) * 2012-06-04 2016-02-29 Опко Байолоджикс Лтд. Пегилированные варианты oxm
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
MX372833B (es) 2012-11-06 2020-06-25 Hanmi Pharm Co Tld Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina.
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
WO2014093343A2 (en) * 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
SI24318A (sl) 2013-03-13 2014-09-30 Diagen D.O.O. Nove stabilne soli pentadekapeptida, postopek za njihovo pripravo, njihova uporaba za izdelavo farmacevtskih pripravkov in njihova uporaba v terapiji
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
US20150050213A1 (en) * 2013-08-14 2015-02-19 University Of Virginia Patent Foundation Compositions and methods for imaging inflammation of traumatic brain injury
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease
US10279023B2 (en) 2013-09-24 2019-05-07 Board Of Regents, The University Of Texas System Mucin-associated surface protein as a vaccine against chagas disease
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PL3086815T3 (pl) 2013-12-27 2022-06-13 Zymeworks Inc. Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe
JP6602834B2 (ja) 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
WO2016019340A1 (en) * 2014-07-31 2016-02-04 Serina Therapeutics, Inc. Polyoxazoline antibody drug conjugates
US10980744B2 (en) 2014-08-08 2021-04-20 The Regents Of The University Of California High density peptide polymers
CA2958939A1 (en) * 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
RU2704259C2 (ru) 2014-10-06 2019-10-25 Гатт Текнолоджиз Б. В. Пористый гемостатический продукт со свойством адгезии к тканям
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
PH12021552108A1 (en) 2014-12-10 2022-05-11 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
CN105777892A (zh) * 2014-12-17 2016-07-20 深圳翰宇药业股份有限公司 普兰林肽聚乙二醇衍生物、其制备方法及其应用
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3988113A1 (en) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20180282383A1 (en) 2015-10-02 2018-10-04 University Of Copenhagen Small molecules blocking histone reader domains
CA3000211A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
KR101642962B1 (ko) 2015-11-05 2016-07-26 (주)제이월드 봉합사 및 그 제조 방법
RU2605385C2 (ru) * 2015-11-23 2016-12-20 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения моноконъюгата полисиаловой кислоты с тимозином бета 4 и ковалентный моноконъюгат полисиаловой кислоты с тимозином бета 4, устойчивый к деградации в токе крови
RU2607527C2 (ru) * 2015-11-23 2017-01-10 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Ковалентный моноконъюгат полиэтиленгликоля с тимозином бета 4, устойчивый к деградации в токе крови, и способ его получения
ES2906791T3 (es) * 2016-02-16 2022-04-20 Strongbridge Dublin Ltd Composiciones farmacéuticas de veldoreotida soluble en agua con escasa solubilidad en condiciones fisiológicas y métodos de producción
US10039801B2 (en) 2016-02-16 2018-08-07 Strongbridge Ireland Limited Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
CN109563145B (zh) 2016-07-11 2024-01-26 Opko生物科学有限公司 长效凝血因子及其制备方法
WO2018057547A1 (en) * 2016-09-21 2018-03-29 Gardner William Graham Dental appliance for use as an aligner and as a tool to reduce temporomandibular dysfunction
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
JP7316222B2 (ja) * 2017-05-15 2023-07-27 ネクター セラピューティクス 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法
WO2019007383A1 (zh) 2017-07-05 2019-01-10 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物
JP7137625B2 (ja) * 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US20220280625A1 (en) * 2019-08-12 2022-09-08 Northwestern University Brush polymers for therapeutic applications
WO2021072349A1 (en) * 2019-10-11 2021-04-15 Tobebio Novel Drug Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer
WO2021111470A1 (en) * 2019-12-03 2021-06-10 Indian Institute Of Technology Delhi A process for preparation of pegylated therapeutic proteins
IL293852A (en) * 2019-12-13 2022-08-01 Folium Labs Inc Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
CN111494318B (zh) * 2020-04-28 2022-04-12 华中科技大学同济医学院附属协和医院 一种肿瘤靶向和还原敏感型复合胶束及其制备方法和应用
WO2022035947A1 (en) * 2020-08-12 2022-02-17 Wisconsin Alumni Research Foundation Conjugation of proteins to polysaccharides using a phosphate bridge
WO2022114906A1 (ko) * 2020-11-30 2022-06-02 세종대학교 산학협력단 신규 퇴행성 신경질환 치료용 약학적 조성물
AU2022233849A1 (en) * 2021-03-08 2023-10-12 Akershus Universitetssykehus Hf Clearance assay
CN113134075B (zh) * 2021-04-29 2024-05-10 江苏普莱医药生物技术有限公司 一种抗菌肽乳膏及其制备方法
US20240408215A1 (en) 2021-09-08 2024-12-12 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Use of diazirine linker for drug conjugates
CN114395597B (zh) * 2021-12-17 2024-04-09 佛山汉腾生物科技有限公司 Glp-1或其变体的羟基化检测方法
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN116036234B (zh) * 2023-01-17 2024-02-06 青岛市中心医院 一种用于治疗骨质疏松的药剂
WO2024249889A1 (en) * 2023-05-31 2024-12-05 University Of Connecticut Genetic sequence/small molecule-carbohydrate conjugates for enhanced lung-specific targeting
CN118666949B (zh) * 2024-06-27 2025-07-29 首都医科大学 熊果酰-Arg-Gly-Asp-Ser的四聚体,其合成,活性和应用
CN118440155B (zh) * 2024-07-11 2024-11-22 中国药科大学 一种双激动多肽化合物及其医药用途

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
IT1017153B (it) * 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
US4010148A (en) * 1975-05-12 1977-03-01 Board Of Regents Of The University Of Texas System Purified thymosin and process
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4247066A (en) * 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
US4321260A (en) 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
ZW17482A1 (en) 1981-08-27 1982-11-17 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
EP0076676B1 (en) 1981-10-05 1986-12-30 Tni Pharmaceuticals, Inc. Process for using endorphins as antitumour agents
US4461724A (en) * 1981-10-28 1984-07-24 Nippon Zoki Pharmaceutical Co., Ltd. Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4805811A (en) * 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US4668281A (en) * 1985-05-20 1987-05-26 E. I. Du Pont De Nemours And Company Thiophenesulfonamides
US5256549A (en) 1986-03-28 1993-10-26 Chiron Corporation Purification of synthetic oligomers
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3634952A1 (de) * 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
AT387234B (de) 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US4966753A (en) 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5049656A (en) * 1988-12-21 1991-09-17 Board Of Regents Of The University Of Nebraska Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5137871A (en) 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
YU176089A (sh) 1989-09-12 1992-09-07 Sikirić, Predrag Postupak za pripremu supstancije bpc i supstancija bpc
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
ES2151476T3 (es) 1990-06-28 2001-01-01 Glaxo Wellcome Inc Formulaciones de farmacos en aerosol.
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE164167T1 (de) 1990-12-21 1998-04-15 Curative Tech Inc Angiogene peptide
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
EP0573608A1 (en) 1991-02-07 1993-12-15 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5817628A (en) 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US5470949A (en) 1992-12-15 1995-11-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for making amino acid glycosides and glycopeptides
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5804558A (en) 1993-07-20 1998-09-08 University Of California Protegrins
US6653442B1 (en) 1993-07-20 2003-11-25 Intrabiotics Pharmaceuticals, Inc. Protegrins
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
IT1271486B (it) 1993-10-12 1997-05-28 Italfarmaco Spa Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5388572A (en) * 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5457044A (en) 1993-10-29 1995-10-10 Genentech, Inc. Method for collection of aerosolized proteins by inert filtration
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
PT735884E (pt) 1993-12-20 2000-09-29 Minnesota Mining & Mfg Formulacoes de aerossol de flunisolida
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US6205999B1 (en) * 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6085740A (en) * 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US6014970A (en) * 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
WO1996032096A1 (en) 1995-04-14 1996-10-17 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6162046A (en) 1995-05-10 2000-12-19 Allports Llc International Liquid vaporization and pressurization apparatus and methods
US6585509B2 (en) * 1995-05-10 2003-07-01 Allports Llc International Vaporization and pressurization of liquid in a porous material
US5692095A (en) 1995-05-10 1997-11-25 Allports, Inc. Capillary feed boiler
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
EP1510524A3 (en) 1995-06-07 2006-06-07 Ortho Pharmaceutical Corporation Compounds and peptides that bind to the erythropoietin receptor
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) * 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AU5806898A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes and compositions for spray drying hydrophobic drugs in organic solventsuspensions of hydrophilic excipients
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP1012189B1 (en) 1997-09-08 2007-10-31 Metabolic Pharmaceuticals Ltd. Treatment of obesity
NZ503464A (en) 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
PL343438A1 (en) * 1998-04-08 2001-08-13 Lilly Co Eli Pulmonary and nasal delivery of raloxifene
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
CA2331925A1 (en) 1998-06-29 2000-01-06 The Center For Blood Research, Inc. Monocyte locomotion inhibitory factor
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
JP4486187B2 (ja) * 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
ATE313384T1 (de) 1999-04-23 2006-01-15 Battelle Memorial Institute Richtungsverstellbarer ehd- aerosol-zerstäuber
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
SE9902627D0 (sv) 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
WO2001024831A2 (en) * 1999-10-04 2001-04-12 Shearwater Corporation Polymer stabilized neuropeptides
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
EP1666028B1 (en) * 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
AU1889101A (en) 1999-12-17 2001-06-25 Takeda Chemical Industries Ltd. Process for producing kiss-1 peptide
PT1259563E (pt) * 1999-12-22 2009-04-14 Nektar Therapeutics Al Corp Processo para a preparação de ésteres de 1-benzotriazolil- -carbonato de polímeros solúveis em água
KR100653153B1 (ko) 1999-12-22 2006-12-01 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체의 입체장애 유도체
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
EP1273658A4 (en) 2000-03-30 2004-08-11 Takeda Chemical Industries Ltd NEW PROTEIN, THEIR DNA AND METHOD FOR THE PRODUCTION THEREOF
US6884778B2 (en) * 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
AU2001274601A1 (en) 2000-06-23 2002-01-02 Kaken Pharmaceutical Co., Ltd. Preventives or remedies for heart failure
US6357490B1 (en) * 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
DK1326630T3 (da) 2000-09-18 2008-09-15 Sanos Bioscience As Anvendelse af GLP-2-peptider
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
WO2002036169A2 (en) 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
US6583408B2 (en) * 2001-05-18 2003-06-24 Battelle Memorial Institute Ionization source utilizing a jet disturber in combination with an ion funnel and method of operation
US6803565B2 (en) 2001-05-18 2004-10-12 Battelle Memorial Institute Ionization source utilizing a multi-capillary inlet and method of operation
TR200400295T2 (tr) * 2001-05-21 2005-04-21 Nektar Therapeutics Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ATE360034T1 (de) 2001-09-19 2007-05-15 Takeda Pharmaceutical Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
CA2466027C (en) 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1442294A4 (en) 2001-11-16 2005-01-19 Waters Investments Ltd CONCENTRATION, DESALINATION AND DEPOT IN PARALLEL ON MALDI TARGETS
US6701922B2 (en) * 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US7458373B2 (en) 2002-01-15 2008-12-02 Philip Morris Usa Inc. Aerosol generator for drug formulation
ATE391742T1 (de) 2002-02-15 2008-04-15 Nektar Therapeutics Al Corp Hydrolytisch abbaubare polyalkylenoxid-polymere
US6634864B1 (en) 2002-02-19 2003-10-21 Vapore, Inc. High fluid flow and pressure in a capillary pump for vaporization of liquid
PL205811B1 (pl) 2002-08-13 2010-05-31 Iwona Bonney Zastosowanie peptydów o działaniu analgetycznym jako substancji czynnej w urządzeniach do podawania leku bezpośrednio do miejsca ich spodziewanego działania przeciwbólowego
BR0314172A (pt) * 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
RU2328505C2 (ru) * 2002-09-11 2008-07-10 Фрезениус Каби Дойчланд Гмбх Полипептиды, обработанные has, особенно эритропоэтин, обработанный has
DE10242076A1 (de) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
ES2375299T3 (es) 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
JP5207590B2 (ja) * 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
US20040136952A1 (en) 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US6800611B2 (en) 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
CA2509939C (en) * 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
EP1620118B1 (en) * 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
JP2006522816A (ja) 2003-04-11 2006-10-05 ピーアール ファーマシューティカルズ， インコーポレイテッド 部位特異的タンパク質結合体を調製する方法
AU2004232847B2 (en) 2003-04-23 2008-11-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
WO2005002597A1 (en) * 2003-07-02 2005-01-13 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
KR101270692B1 (ko) * 2003-08-12 2013-06-03 리폭센 테크놀로지즈 리미티드 폴리시알산 유도체
JP5632119B2 (ja) 2003-09-17 2014-11-26 ウェルズ ファーゴ バンク ナショナル アソシエイション 多分岐ポリマーのプロドラッグ
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
AU2003304553A1 (en) 2003-10-21 2005-06-08 Robert Lerner Improved capillary pumps for vaporization of liquids
EP2239273B1 (en) * 2003-11-13 2013-10-09 Hanmi Science Co., Ltd. A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
AU2005231342A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
US7290541B2 (en) 2004-04-20 2007-11-06 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
US7946291B2 (en) 2004-04-20 2011-05-24 Novartis Ag Ventilation systems and methods employing aerosol generators
EP1750513A4 (en) 2004-04-23 2009-07-22 Serono Lab USE OF GPCR54 LIGANDS FOR THE TREATMENT OF BARRENESS
CN100355786C (zh) 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2573262C (en) 2004-07-16 2015-02-10 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
EP1838331A4 (en) 2004-12-15 2012-12-26 Univ Colorado ANTIMICROBIAL PEPTIDES AND METHOD OF USE
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
GB0501008D0 (en) 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
HUE026231T2 (en) 2005-04-07 2016-06-28 Cardiorentis Ag Use of a natriuretic peptide for the treatment of heart failure
EP1885403B1 (en) * 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1896662B1 (en) 2005-05-25 2014-07-23 AeroGen, Inc. Vibration systems and methods
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
AU2006289259A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007034498A1 (en) * 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
CN100577685C (zh) 2005-11-10 2010-01-06 中国人民解放军军事医学科学院毒物药物研究所 长效胸腺素α1的聚乙二醇化修饰物
EP1968644B1 (en) * 2005-12-16 2012-06-27 Nektar Therapeutics Polymer conjugates of glp-1
EP1797901A1 (en) 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20070213275A1 (en) 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
EP2038424A2 (en) 2006-06-21 2009-03-25 Enzon Pharmaceuticals, Inc. Stabilized proteins
WO2008011165A2 (en) * 2006-07-21 2008-01-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
EP2073832B1 (en) 2006-09-13 2013-09-04 The Trustees of Columbia University in the City of New York Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
JP2008156283A (ja) * 2006-12-25 2008-07-10 Kyowa Hakko Kogyo Co Ltd 水溶性ポリマー修飾ポリペプチドの製造方法
CA2671676C (en) * 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
RU2007137048A (ru) 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
JP5933923B2 (ja) 2007-10-09 2016-06-22 ポリテリクス リミテッド 新規な複合タンパク質及びペプチド
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
US20110171162A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
US20110171163A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
US20110171161A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
WO2010033204A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010042145A1 (en) 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033217A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
US20110171165A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2334333A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of v681-like peptides
EP2340047A1 (en) 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
US20110171166A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
US20110237524A1 (en) 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033239A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of biphalin peptides

Also Published As

Publication number Publication date
WO2010033207A1 (en) 2010-03-25
WO2010033240A2 (en) 2010-03-25
US9173951B2 (en) 2015-11-03
EP2350118B1 (en) 2016-03-30
CA2737040C (en) 2017-05-02
US9682153B2 (en) 2017-06-20
US20110166063A1 (en) 2011-07-07
WO2010033240A3 (en) 2010-06-17
US20160022828A1 (en) 2016-01-28
AU2009292643B2 (en) 2016-02-18
JP2012502990A (ja) 2012-02-02
EP2341942A1 (en) 2011-07-13
JP2015134832A (ja) 2015-07-27
US8680263B2 (en) 2014-03-25
CA2737040A1 (en) 2010-03-25
US20150051371A1 (en) 2015-02-19
AU2009292643A1 (en) 2010-03-25
EP2898900A1 (en) 2015-07-29
US20110171716A1 (en) 2011-07-14
EP2898900B1 (en) 2017-11-15
MX2011003117A (es) 2011-04-21
EP2350118A2 (en) 2011-08-03
US20190070251A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP5765813B2 (ja) 治療用ペプチドのポリマーコンジュゲート
CA2624175C (en) Cgrp peptide antagonists and conjugates
US8449872B2 (en) Polymer conjugates of nesiritide peptides
US7897573B2 (en) Selective VPAC2 receptor peptide agonists
CN113710692A (zh) 长效glp-2类似物
US20090082276A1 (en) Selective vpac2 receptor peptide agonists
WO2010033224A1 (en) Polymer conjugates of kiss1 peptides
US20090118167A1 (en) Selective Vpac2 Receptor Peptide Agonists
US20060105948A1 (en) GLP-2 derivatives
US9763995B2 (en) Polymer conjugates of protegrin peptides
US20110165113A1 (en) Polymer conjugates of v681-like peptides
US20110237524A1 (en) Polymer conjugates of aod-like peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120706

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140627

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150612

R150 Certificate of patent or registration of utility model

Ref document number: 5765813

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees